Skip to content
Back to AVTX

Avalo Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
41
Purchases
0
Sales
41
Purchase value
$0.00
Sale value
$8.34M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Christopher Ryan SullivanChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Sep 18, 2026Period of report Sep 16, 20260001810417-26-000023
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 16, 2026
Common StockF1F212,394$16.3335$202.44K39,900Direct
Filing footnotes · 3
  1. F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
  2. F2The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.
Open on SEC EDGAR
Christopher Ryan SullivanChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Sep 11, 2026Period of report Sep 10, 20260001810417-26-000021
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 10, 2026
Common StockF1F210,185$17.6197$179.46K39,900Direct
Filing footnotes · 3
  1. F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
  2. F2The reported securities were sold in multiple transactions at prices ranging from $17.17 to $17.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Sep 1, 2026Period of report Aug 28, 20260001918845-26-000031
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 28, 2026
Common StockF1679$20.00$13.58K51,776Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Christopher Ryan SullivanChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Aug 19, 2026Period of report Aug 17, 20260001810417-26-000019
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 18, 2026
Common StockF431,031$20.0549$622.32K39,900Direct
SaleAug 17, 2026
Common StockF1F237,945$19.8533$753.33K43,649Direct
SaleAug 17, 2026
Common StockF33,749$19.9419$74.76K39,900Direct
Filing footnotes · 5
  1. F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
  2. F2The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  4. F4The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  5. F5The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Aug 19, 2026Period of report Aug 17, 20260001918845-26-000029
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 17, 2026
Common StockF11,000$20.00$20.00K51,776Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Jennifer RileyChief Strategy Officer
4
Filed Aug 12, 2026Period of report Aug 11, 20260002047607-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 11, 2026
Common StockF12,655$19.5903$52.01K37,041Direct
Filing footnotes · 1
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $19.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Aug 12, 2026Period of report Aug 10, 20260001918845-26-000026
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 10, 2026
Common StockF1679$20.00$13.58K51,776Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Jul 29, 2026Period of report Jul 27, 20260001918845-26-000024
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 27, 2026
Common StockF11,000$20.00$20.00K51,776Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Jul 2, 2026Period of report Jun 30, 20260001918845-26-000022
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 30, 2026
Common StockF14,654$20.00$93.08K51,776Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
  3. F3The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Jun 25, 2026Period of report Jun 23, 20260001918845-26-000020
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 23, 2026
Common StockF11,450$18.00$26.10K51,776Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Jun 1, 2026Period of report May 28, 20260001918845-26-000016
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 28, 2026
Common StockF1679$16.00$10.86K47,122Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed May 19, 2026Period of report May 15, 20260001918845-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 15, 2026
Common StockF13,000$18.76$56.28K3,622Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Christopher Ryan SullivanChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed May 11, 2026Period of report May 7, 20260001810417-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 7, 2026
Common StockF1F218,606$24.1222$448.82K423Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
  2. F2The reported securities were sold in multiple transactions at prices ranging from $24.05 to $24.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed May 7, 2026Period of report May 5, 20260001918845-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 6, 2026
Common StockF1F227,538$18.0262$496.41K82,639Direct
SaleMay 6, 2026
Common StockF1F35,000$19.6502$98.25K77,639Direct
SaleMay 6, 2026
Common StockF1F444,944$21.1968$952.67K32,695Direct
SaleMay 6, 2026
Common StockF1F519,015$22.406$426.05K13,680Direct
SaleMay 6, 2026
Common StockF110,058$22.88$230.13K3,622Direct
SaleMay 5, 2026
Common StockF11,679$16.00$26.86K3,622Direct
Filing footnotes · 7
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3The reported securities were sold in multiple transactions at prices ranging from $19.08 to $19.99. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  4. F4The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  5. F5The reported securities were sold in multiple transactions at prices ranging from $21.83 to $22.80. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  6. F6The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
  7. F7The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Christopher Ryan SullivanChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed May 7, 2026Period of report May 6, 20260001810417-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 6, 2026
Common StockF1F213,834$18.5525$256.66K33,589Direct
SaleMay 6, 2026
Common StockF1F312,347$19.2835$238.09K21,242Direct
SaleMay 6, 2026
Common StockF1F42,700$20.76$56.05K18,542Direct
SaleMay 6, 2026
Common StockF1F59,219$21.3698$197.01K9,323Direct
SaleMay 6, 2026
Common StockF1F68,900$22.5745$200.91K423Direct
Filing footnotes · 7
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
  2. F2The reported securities were sold in multiple transactions at prices ranging from $17.95 to $18.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3The reported securities were sold in multiple transactions at prices ranging from $19.02 to $19.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  4. F4The reported securities were sold in multiple transactions at prices ranging from $20.04 to $20.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  5. F5The reported securities were sold in multiple transactions at prices ranging from $21.10 to $21.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  6. F6The reported securities were sold in multiple transactions at prices ranging from $22.26 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  7. F7The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.
Open on SEC EDGAR
Mitchell ChanDirector
4Rule 10b5-1 plan disclosed
Filed May 7, 2026Period of report May 6, 20260001789335-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 6, 2026
Common StockF13,167$22.88$72.46K3,166Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.
Open on SEC EDGAR
Paul VarkiChief Legal Officer
4Rule 10b5-1 plan disclosed
Filed May 7, 2026Period of report May 6, 20260001677896-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 6, 2026
Common StockF1F237,375$18.912$706.84K41,322Direct
SaleMay 6, 2026
Common StockF1F35,196$19.7812$102.78K36,126Direct
SaleMay 6, 2026
Common StockF1F422,839$21.2155$484.54K13,287Direct
SaleMay 6, 2026
Common StockF1F59,253$22.6985$210.03K4,034Direct
SaleMay 6, 2026
Common StockF1400$23.71$9.48K3,634Direct
Filing footnotes · 7
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
  2. F2The reported securities were sold in multiple transactions at prices ranging from $18.50 to $19.495. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3The reported securities were sold in multiple transactions at prices ranging from $19.50 to $19.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  4. F4The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  5. F5The reported securities were sold in multiple transactions at prices ranging from $22.15 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  6. F6Twenty-five percent (25%) of the Option Shares vest on June 24, 2025 and the remainder of the Option Shares will vest in equal monthly installments on the first day of each month thereafter over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date.
  7. F7The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.
Open on SEC EDGAR
Christopher Ryan SullivanChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed May 1, 2026Period of report Apr 29, 20260001810417-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 30, 2026
Common StockF1F38,457$13.2261$111.85K423Direct
SaleApr 29, 2026
Common StockF1F28,458$13.0925$110.74K8,880Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
  2. F2The reported securities were sold in multiple transactions at prices ranging from $12.74 to $13.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3The reported securities were sold in multiple transactions at prices ranging from $12.61 to $13.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Apr 8, 2026Period of report Apr 6, 20260001918845-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 6, 2026
Common StockF1F23,970$18.0122$71.51K3,622Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Christopher Ryan SullivanChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Apr 3, 2026Period of report Apr 1, 20260001810417-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 2, 2026
Common StockF1F46,200$17.0247$105.55K19,118Direct
SaleApr 2, 2026
Common StockF1F51,780$17.5674$31.27K17,338Direct
SaleApr 1, 2026
Common StockF1F2500$15.858$7.93K32,797Direct
SaleApr 1, 2026
Common StockF1F37,479$16.8259$125.84K25,318Direct
Filing footnotes · 5
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
  2. F2The reported securities were sold in multiple transactions at prices ranging from $15.24 to $16.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. F3The reported securities were sold in multiple transactions at prices ranging from $16.45 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  4. F4The reported securities were sold in multiple transactions at prices ranging from $16.385 to $17.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  5. F5The reported securities were sold in multiple transactions at prices ranging from $17.39 to $17.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Apr 3, 2026Period of report Apr 1, 20260001918845-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 1, 2026
Common StockF1679$16.00$10.86K3,622Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Mittie DoyleChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Mar 18, 2026Period of report Mar 16, 20260001918845-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 16, 2026
Common StockF125,492$16.1465$411.61K3,622Direct
Filing footnotes · 3
  1. F1The reported securities were sold in multiple transactions at prices ranging from $16.00 to $16.34. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  2. F2The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
  3. F3The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.